The faculty open by describing HER2-mutant non-small cell lung cancer (NSCLC) as ‘the poor sibling of EGFR-mutant disease’, a comparison one of the panelists derived from an editorial.
Back
Efficacy, Tolerability, and Sequencing in the First-Line Setting for HER2- Mutant Non-Small Cell Lung Cancer
Three thoracic oncologists review first-line treatment of HER2-mutant nonsmall cell lung cancer, including where each option fits in their practice, biomarker testing, diarrhea and organ monitoring, access to oral therapy, sequencing, central nervous system disease, and ongoing research.
Efficacy, Tolerability, and Sequencing in the First-Line Setting for HER2- Mutant Non-Small Cell Lung Cancer
Episodes
All
All
The faculty discuss why HER2 results are confusing to read.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Pimicotinib for Symptomatic TGCT
2
Mo-Rez Responses Span B7-H4 Expression Levels in Platinum-Resistant Ovarian Cancer in BEHOLD-1 Biomarker Analysis
3
Genomic Testing, Toxicity, and Sequencing Shape Treatment Decisions in Advanced Prostate Cancer
4
Dr Natsuhara on Treatment Advances and Research Considerations in TNBC
5